.aspx?width=300&height=190&ext=.jpg&type=BlockColumn1Zoom1)
The Mycobacterial Cohort Study (MyCoS) stores biomaterial (plasma, serum, PBMC’s, PAXgene and DNA) from patients being treated at Radboudumc for a mycobacterial infection, together with data about the patient's disease course. Through the MyCoS biobank a platform will be created to answer diagnostic, pathophysiological and prognostic questions about mycobacterial infections.
-
Want to know more about these subjects? Click on the buttons below for more news.
Related news items
Dutch-Nordic Alliance for Precision Cancer Medicine launched
26 November 2021The Nordic countries (Denmark, Sweden, Norway, and Finland) are together setting up national clinical precision cancer trials modelled on the very successful DRUP trial in the Netherlands.
read more
New Automated PBMC isolation method introduced in LMI.
21 September 2021The Radboud Biobank (RB) and the laboratory of Medical Immunology (LMI) are making plans to replace the density gradient centrifugation method with a new automated PBMC isolation method, the AutoMACS Pro Separator.
read more
Health-RI, geared up to accelerate
21 September 2021The Dutch cabinet has selected Health-RI's National Growth Fund proposal for a national health data infrastructure. On 5 October, the kick-off will take place during a live meeting in Jaarbeurs Media Plaza in Utrecht.
read more
SUNRISE-CRC sub-biobank
21 September 2021The main purpose of SUNRISE-CRC is to determine whether treatment with a high dose of sunitinib provides a better chance of survival and slows the progression of (colo)rectal cancer (CRC) more than standard treatment with TAS-102.
read more
PRECISE sub-biobank
21 September 2021The aim of the PRECISE biobank is to develop the first, smart multi-modal liquid biopsy test service for the prediction of immune checkpoint inhibitor response in urothelial cancer (UC) patients – the PRECISE IVD.
read more